Stock Analysis, Dividends, Split History

MSRT / MassRoots, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.82
Volume406,700.00
Market Cap ($M)133.27
Enterprise Value ($M)133.25
Book Value ($M)-2.81
Book Value / Share-0.02
Price / Book-47.35
NCAV ($M)-3.95
NCAV / Share-0.02
Price / NCAV-33.70
Share Statistics
Common Shares Outstanding 153,944,886
Common Stock Shares Outstanding 112,165,839
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)3.90
Return on Assets (ROA)-61.34
Return on Equity (ROE)40.53
Balance Sheet (mrq) ($M)
Assets1.27
Liabilities4.09
Quick Ration/a
Current Ratio0.03
Income Statement (mra) ($M)
Advertising Revenue319,242.00
Revenues0.00
Operating Income-36.80
Net Income-44.39
Earnings Per Share Basic And Diluted-0.46
Cash Flow Statement (mra) ($M)
Cash From Operations-8.00
Cash from Investing-0.31
Cash from Financing-0.31
Identifiers and Descriptors
CUSIP57630J106
Central Index Key (CIK)1589149

Split History

Stock splits are used by MassRoots, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

The CannaGuide: Complete Cannabis Coverage - Aphria Part 1 - Full Operations, Partnerships, And Investments Overview

2018-08-23 seekingalpha
Part 1 in the CannaGuide on Aphria covering the companies current operations, expansion plans, and strategic partnerships/investments. (92-6)

MassRoots Inc.'s (MSRT) CEO Isaac Dietrich on 2018 Quarterly Shareholder Update Call Results - Earnings Call Transcript

2018-08-15 seekingalpha
Greetings and welcome to the MassRoots Quarterly Shareholder Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to Jesus Quintero. Please go ahead.

Stockholders Of MassRoots Are Ready To Sell 28.8% Of The Total Shares Outstanding At 146x Sales

2018-07-23 seekingalpha
Stockholders are trying to resell 51.4 million shares acquired in private placements. The transaction could make the share price decline. (0-1)

High Times refreshes IPO plans as cannabis companies build buzz on Wall St

2018-06-19 reuters
(Reuters) - The company that owns High Times, a magazine devoted to marijuana culture, announced on Tuesday that it is launching an equity crowdfunding campaign ahead of its application for an initial public offering on Nasdaq later this year. (13-0)

MassRoots: Building A New Potemkin Business Under The Spectre Of An Old Dying One

2018-04-25 seekingalpha
The company's latest charade is focused around its Blockchain Technologies Inc. subsidiary, a business created around the peak of the cryptocurrency bubble.

CUSIP: 57630J106